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Introduction: The risk of contralateral lymph node metastases following unilateral 
sentinel lymph node (SLN) metastases in patients with vulvar cancer(s) remains to be 
systematically assessed.
Material and methods: We performed a multicenter, retrospective registry- based 
study of 476 patients with vulvar cancer. The primary outcome measure was the rate 
of contralateral non- SLN metastases in the case of positive unilateral SLN.
Results: Out of 476 patients with primary vulvar cancer, 202 received SLN biopsy: 
58 unilateral and 144 bilateral. Out of 66 patients with unilateral metastatic SLN, 62 
(93.9%) received contralateral lymphadenectomy— 18 after unilateral and 44 after bi-
lateral SLN biopsy. In the study group, 132 SLN were assessed with a median number 
of 2 (range 1– 4) per patient and 76 of these were positive. Lymph node- positivity was 
associated with advanced tumor stage, as well as lymph and vascular space invasion. 
In the group of patients with bilateral inguino- femoral lymphadenectomy, 1004 lymph 
nodes were resected with a median number of 15 (range 10– 29) per patient. After full 
dissection of the inguino- femoral lymph nodes, no contralateral non- SLN metastases 
were found.
Conclusions: The risk of contralateral non- SLN metastases in patients with unilateral 
SLN metastases was low. Therefore, the impact of contralateral lymphadenectomy on 
patient survival should be investigated in further studies.
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1  |  INTRODUC TION
Metastases in inguinofemoral lymph nodes (LN) remains the most impor-
tant prognostic factor for survival of patients with vulvar cancer,1 high-
lighting the essential role of LN staging. The data of the GROINSS- V trial 
demonstrated the diagnostic relevance of the sentinel lymph node (SLN) 
procedure for patients with clinically node- negative disease.2 The sig-
nificant reduction of treatment- related morbidity and the excellent long- 
term outcome,3 resulted in the wide adoption of this procedure as the 
standard of care. Nevertheless, some controversies regarding LN stag-
ing remain unresolved. One of the most important questions is whether 
contralateral groin lymphadenectomy should be performed in the case 
of unilateral SLN metastases. Some older studies suggested an increased 
risk of contralateral groin metastases upon unilateral metastasis.4,5 
Notably, SLN biopsy has not been performed in these studies. After the 
introduction of SLN biopsy,2 no increased numbers of contralateral LN 
metastases were observed in studies with limited numbers of patients.6,7 
Current German and European guidelines recommend a contralateral 
lymphadenectomy in the case of ipsilateral LN metastases.1,8
The aim of this study was to evaluate the rate of contralateral 
non- SLN metastases in vulvar cancer patients with unilateral SLN 
metastases.
2  |  MATERIAL AND METHODS
2.1  |  Patients
We investigated cases of squamous and adenosquamous vulvar can-
cer included in the prospectively maintained regional cancer registry 
of Saxony- Anhalt, a federal state of Germany. These population- based 
data originate from medical reports, pathology and follow- up records. 
Documented parameters comprise diagnosis, therapies, course of dis-
ease and long- term follow up, including locoregional or distant recur-
rence and death.9 The date and cause of death are documented in the 
registry by the main health department shortly after death. In this co-
hort study, we analyzed women who were diagnosed with vulvar can-
cer between January 2000 and September 2017. Overall, 476 patients 
were assessed for inclusion in the present study (Figure 1). Patients 
who did not receive an SLN biopsy (n = 263) and patients with missing 
information regarding lymphadenectomy (n = 7) or with basaloid car-
cinoma (n = 4) were excluded, as were patients who had negative SLN 
(n = 131), bilateral SLN metastases (n = 5), or who did not receive con-
tralateral lymphadenectomy despite having unilateral SLN metastases 
(n = 4). The remaining 62 patients who had unilateral SLN metastases 
and underwent contralateral lymphadenectomy were further investi-
gated. For these patients, tumor localization was investigated by clas-
sifying the tumors as lateral lesions (>1 cm from the midline) or midline 
lesions (≤1 cm from the midline). The surgical approach and the SLN 
procedure were performed in accordance with the institutional proce-
dure. Biopsy of SLN was performed for patients with clinically negative 
nodes and tumors <4 cm. The SLN were labeled by 99mTc- nanocolloid 
and detected by gamma counter. The identified SLN were sent for 
frozen- section analysis. Bilateral lymphadenectomy was performed in 
cases of positive SLN(s). In the case of negative frozen sections, hema-
toxylin and eosin staining of the LN was performed. In a case of positiv-
ity, a secondary lymphadenectomy was performed. Ultrastaging of all 
negative LN was performed after 2009. The manuscript was prepared 
in accordance with the STROBE statement criteria.10
2.2  |  Statistical analysis
Statistical analyses were performed using SPSS version 26.0 (IBM). 
Correlation of variables was assessed using chi- squared test and 
two- sided Student's t test for continuous variables. Values of p 
below the significance level (α) of 0.05 were considered statistically 
significant. Continuous variables are presented as means and ranges 
and categorical variables are presented as numbers.
2.3  |  Ethical approval
The Ethics Committee of the Otto- von- Guericke University, 
Magdeburg, Germany concluded that no informed consent was 
Key message
The role of contralateral lymphadenectomy in patients 
with vulvar cancer and a unilateral metastatic sentinel 
lymph node is debatable. In our population- based study 
the risk of contralateral metastases in such patients was 
low. Additional studies are needed.
F I G U R E  1  Schematic representation of the study design. SLN, 
sentinel lymph node
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required for this retrospective, observational study (ID: 143/15; 
October 28, 2015). Before analysis, patient data were subjected to 
pseudonymization.
3  |  RESULTS
Between January 2000 and September 2017, 472 women with vul-
var cancer were identified. The flow diagram shows the study design 
and the number of patients at each stage of the study (Figure 1). 
From the 202 patients included in the initial analysis, 71 (35.1%) ex-
hibited SLN metastases (Table 1). SLN metastases were associated 
with advanced tumor stage (p = 0.0001) and lymph space invasion 
(p = 0.0001). Patient's age, histological grade and vascular space in-
vasion did not show any association with SLN metastases. SLN me-
tastases were observed unilaterally and bilaterally in 66 (93.0%) and 
5 (7.0%) patients, respectively. Of special interest were the patients 
in the former category, so we focused on these 62 patients with 
unilateral SLN metastases, of which 18 (29.0%) underwent a unilat-
eral and the remaining 44 (71%) a bilateral SLN biopsy (Figure 1). 
Of these patients, 54 had no additional LN metastases, whereas 
in eight women a non- SLN metastasis was observed (Table 1). The 
presence of additional LN was associated with lymph space invasion 
(p = 0.039). Patient's age, tumor size, tumor localization, tumor grad-
ing, and vascular space invasion were not associated with any addi-
tional non- SLN metastases (Table 2). The performance of unilateral 
or bilateral SLN biopsy was associated with the tumor localization. 
Only two (5.7%) of 35 patients with median tumor localization and 
15 (65.2%) of 23 patients with lateral localized tumors underwent a 
unilateral SLN biopsy (p = 0.0001). Moreover, the tumor localization 
correlated with the localization of the LN metastases. In 5 (12.5%) 
of 40 patients with median tumors and in 0 (0%) of 23 patients with 
lateral tumors bilateral metastases were observed. Nevertheless, 
this correlation was not significant (p = 0.077). During the follow- up 
period of 35 months (range 1– 114 months), a recurrence was ob-
served in 12 (22.6%) patients, more specifically 7 (11.3%) vulvar, 5 
(8.1%) groin and 2 (3.2%) distant recurrences. Interestingly, four of 
the groin metastases were on the contralateral side to the primary 
SLN biopsy. Notably, only three of the patients with groin recurrence 
received an adjuvant therapy. The other two patients refused the 
therapy.
In this group of patients, overall 132 SLN were removed (Table 3) 
in the group of patients with a bilateral SLN procedure and 42 in the 
group with unilateral SLN biopsy. The median number of removed 
SLN was 2 (range 1– 4) per patient. Metastases to LN were observed 
in 76 SLN: one SLN metastasis in 48 (21.6%) women and two SLN 
metastases in 14 (18.4%) women. After bilateral lymphadenectomy, 
1004 LN were removed with a median number of 15 (range 10– 
29) per patient. Among these, 89 LN metastases were observed. 
However, in the case of unilateral SLN metastases, no contralateral 
non- SLN metastases were found.
4  |  DISCUSSION
In the present study, we found no positive association between uni-
lateral SLN metastases and contralateral non- SLN metastases in pa-
tients with primary vulvar cancer. These findings put into question 
Variable Total
Lymph nodes p value
Negative Positive
N % N %
Total 202 131 64.9 71 35.1
Age (years), mean 
(range)
202 75 (33– 95) 72 (34– 91) 0.085
Tumor stage
pT1 108 83 63.4 25 35.2 0.0001
pT2 86 46 35.1 40 56.3
pT3 8 2 1.5 6 8.5
Histological grade
1 27 22 16.8 5 7.0 0.148
2 123 76 58.0 47 66.2
3 52 33 25.2 19 26.8
Lymph space invasion
Negative 108 89 74.8 19 27.9 0.0001
Positive 79 30 25.2 49 72.1
Vascular space invasion
Negative 159 109 94.8 50 86.2 0.074
Positive 14 6 5.2 8 13.8
TA B L E  1  Clinical and pathological 
characteristics of the study cohort
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the current standard of practice of contralateral lymphadenectomy 
for women with unilateral SLN metastases.1,8
The above- mentioned recommendations are based on older 
studies that suggested an increased risk of contralateral LN metas-
tases in patients with vulvar cancer and confirmed unilateral LN me-
tastasis. In a study with 195 patients with vulvar cancer, systematic 
bilateral inguinal and pelvic lymphadenectomy was performed.5 The 
rate of LN metastases was 21% with an ipsilateral spread of 84.6%. 
In the case of a lateral tumor, contralateral LN metastases occurred 
in 15.3% and 30.7% of patients without and with ipsilateral positive 
LN, respectively. In general, bilateral involvement of the groin LN 
was observed in 60.0% of bilateral labial lesions, 29.6% of unilateral 
labial lesions and 37.5% of clitoral lesions.5 These results demon-
strate the strong association between tumor localization and LN 
metastases. In a further study, the relationship between the contra-
lateral involvement of the groin LN and tumor localization was inves-
tigated.4 The risks of contralateral LN involvement were 1.8% and 
9.5% for unilateral and mediolateral tumors, respectively. No contra-
lateral LN metastases were observed in patients in whom the tumor 
size was ≤2 cm with an invasion depth of ≤5 mm. The reduced risk of 
contralateral LN metastases in patients with lateral lesions was fur-
ther documented in another study with tumors localized >1 cm from 
the midline.11 Importantly, these studies were conducted before the 
era of SLN biopsy, so lack the accuracy and precision of results ob-
tained by the SLN procedure.
A recent study investigated the rate of contralateral non- SLN 
metastases in 28 patients with vulvar cancer.7 In agreement with 
our results, the authors did not find any contralateral non- SLN me-
tastasis after bilateral lymphadenectomy in the case of unilateral 
metastatic SLN. Moreover, the clinical and pathological character-
istics of the patients in this study were comparable with our cohort. 
Importantly, in this study the patients underwent bilateral SLN bi-
opsy and demonstrated a negative contralateral SLN in patient with 
metastatic ipsilateral SLN. In our cohort, 44 patients had similar con-
ditions. In another recent study, Nica and co- workers analyzed 19 
patients, who had unilateral positive SLN and underwent bilateral 
lymphadenectomy.6 Thirteen of these patients (68.4%) had midline 
and six (31.6%) had lateral tumors, which mirrors the tumor localiza-
tion in our cohort; the midline tumors in our study population were 
60.3%. Notably, the authors observed in one patient (5.3%) a con-
tralateral non- SLN metastasis with a lesion sized 6 cm. Importantly, 
direct comparison with our results is difficult because Nica et al. 
included also tumors with a diameter of >4 cm in their analysis.6 
Therefore, these data should be interpreted with caution. In our 
cohort, only patients with lesions <4 cm were included, for whom 
the effectiveness and safety has been documented.3 In contrast, 
Winarno et al. have recently demonstrated that 4 of 18 (22.2%) 
women with unilateral SLN metastasis had contralateral inguino- 
femoral groin metastases.12 Notably, the rate of contralateral LN 
metastases in this cohort correlated significantly with the depth of 
Variable




N % N %
Total 54 87.1 8 12.9
Age (years), mean (± SD) 72 (± 13) 74 (± 12) 0.954
Tumor stage
pT1 21 38.9 4 50.0 0.560
pT2 30 55.6 3 37.5
pT3 3 5.6 1 12.5
Tumor localization
≤1 cm from the midline 30 60.0 5 32.5 0.893
>1 cm from the midline 20 40.0 3 37.5
Histological grade
1 5 9.3 0 0 0.409
2 35 64.8 7 87.5
3 14 25.9 1 12.5
Lymph space invasion
Negative 19 36.5 0 0 0.039
Positive 33 63.5 8 100
Vascular space invasion
Negative 39 88.6 4 66.7 0.146
Positive 5 11.4 2 33.3
TA B L E  2  Clinical and pathological 
characteristics of the patients with non- 
sentinel lymph node metastases
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infiltration. In our cohort, this factor was not evaluated. Therefore, 
the comparison of the data should be interpreted with caution.
In conclusion, our data demonstrate that lymphadenectomy of 
the contralateral groin in cases of unilateral SLN groin metastasis in 
patients with vulvar cancer <4 cm was not associated with additional 
LN metastases and this has been confirmed by others.6,7 The study 
design and the number of patients included do not allow any conclu-
sion on safety of lymphadenectomy to be drawn.
The preoperative evaluation of the LN in patients with vulvar cancer 
is important and should be used to select appropriate patients for sen-
tinel approach.13,14 As suggested by the current German and European 
Society of Gynaecological Oncology guidelines in patients with small- 
volume lateral tumors and no clinically suspicious LN, the contralateral 
lymphadenectomy could be omitted.1,8 However, contralateral lymph-
adenectomy may be performed when ipsilateral LN are metastatic.
In our cohort, bilateral sentinel LN metastases were observed 
only in patients with median tumors. No contralateral metastases 
were found in patients with laterally localized tumors. As suggested 
by the guidelines, the tumor localization should be considered during 
performance of the SLN biopsy.1,8 We have found that most unilat-
eral SLN biopsies were performed in patients with lateral tumors. In 
the case of median tumors, unilateral SLN biopsy was performed in 
5.6%.
Limitations of our study are its retrospective character, the rel-
atively short median follow up and missing information regarding 
depth of tumor infiltration and micrometastases in the LN. Based 
on the small number of patients our data need further investigation 
in larger cohorts. Furthermore, the use of dual labeling with 99mTc- 
nanocolloid and blue dye as well as the reason for omitting adju-
vant therapy in a case of LN metastases was not evaluated, which 
is an important limitation of the study. The strengths of the present 
study, on the other hand, are the relatively large sample size of pa-
tients with this rare constellation of unilateral SLN metastasis and 
contralateral lymphadenectomy and the high level of external va-
lidity (multicentric population- based study). Further studies should 
be performed to confirm our findings in larger cohorts of patients.
5  |  CONCLUSION
The risk of contralateral LN metastases in patients with unilateral 
SLN metastases is low. However, the limitations do not allow us to 
draw general conclusions, whether contralateral lymphadenectomy 
should be performed or not. Further studies are needed.
CONFLIC TS OF INTERE S T
None.
AUTHOR CONTRIBUTIONS
TI, SI, HE, AI designed the study. TI, JG, JM collected clinical data. 
TI, JG, MB, HE, AI performed statistical analyses. SI, JM, OO, con-
tributed methodological know- how. TI, JG, MB, HE, AI drafted the 
manuscript.
ORCID
Atanas Ignatov  https://orcid.org/0000-0002-9006-4029 
R E FE R E N C E S
 1. National German Guideline S2k. Diagnosis, therapy, and follow- up 
care of vulvar cnacer and its precursors, AWMF Registry No. 
015/059. 2015
 2. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dis-
section is safe in the treatment of early- stage vulvar cancer. J Clin 
Oncol. 2008;26:884- 889.
 3. Te Grootenhuis NC, van der Zee AG, van Doorn HC, et al. Sentinel 
nodes in vulvar cancer: Long- term follow- up of the GROningen 
INternational Study on Sentinel nodes in Vulvar cancer (GROINSS- V) 
I. Gynecol Oncol. 2016;140:8- 14.
 4. Gonzalez Bosquet J, Magrina JF, Magtibay PM, et al. Patterns of 
inguinal groin metastases in squamous cell carcinoma of the vulva. 
Gynecol Oncol. 2007;105:742- 746.
 5. Krupp PJ, Bohm JW. Lymph gland metastases in invasive squamous 
cell cancer of the vulva. Am J Obstet Gynecol. 1978;130:943- 952.
 6. Nica A, Covens A, Vicus D, et al. Sentinel lymph nodes in vulvar 
cancer: Management dilemmas in patients with positive nodes and 
larger tumors. Gynecol Oncol. 2019;152:94- 100.
 7. Woelber L, Eulenburg C, Grimm D, et al. The Risk of Contralateral 
Non- sentinel Metastasis in Patients with Primary Vulvar 
Cancer and Unilaterally Positive Sentinel Node. Ann Surg Oncol. 
2016;23:2508- 2514.
 8. ESGO guidelines: https://guide lines.esgo.org/media/ 2016/08/
ESGO- Vulva r- cance r- Compl ete- repor t- fxd2.pdf
 9. Ignatov T, Eggemann H, Burger E, Costa SD, Ignatov A. Adjuvant ra-
diotherapy for vulvar cancer with close or positive surgical margins. 
J Cancer Res Clin Oncol. 2016;142:489- 495.
 10. von Elm E, Altman DG, Egger M, et al. The Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) 
statement: guidelines for reporting observational studies. Lancet. 
2007;370:1453- 1457.
 11. Andrews SJ, Williams BT, DePriest PD, et al. Therapeutic implica-
tions of lymph nodal spread in lateral T1 and T2 squamous cell car-
cinoma of the vulva. Gynecol Oncol. 1994;55:41- 46.













LN median (± SD) 15 (± 6)
LN+ 89
Contralateral LN+ 0
Abbreviation: LN, lymph node; SLN, sentinel lymph node.
6  |    IGNATOV eT Al.
 12. Winarno AS, Mondal A, Martignoni FC, Fehm TN, Hampl M. The 
potential risk of contralateral non- sentinel groin node metastasis 
in women with early primary vulvar cancer following unilateral 
sentinel node metastasis: a single center evaluation in University 
Hospital of Dusseldorf. BMC Womens Health. 2021;21:23.
 13. Garganese G, Collarino A, Fragomeni SM, et al. Groin sentinel node 
biopsy and 18F- FDG PET/CT- supported preoperative lymph node 
assessment in cN0 patients with vulvar cancer currently unfit for 
minimally invasive inguinal surgery: The GroSNaPET study. Eur J 
Surg Oncol. 2017;43:1776- 1783.
 14. Garganese G, Fragomeni SM, Pasciuto T, et al. Ultrasound mor-
phometric and cytologic preoperative assessment of inguinal 
lymph- node status in women with vulvar cancer: MorphoNode 
study. Ultrasound Obstet Gynecol. 2020;55:401- 410.
How to cite this article: Ignatov T, Gaßner J, Bozukova M, et 
al. Contralateral lymph node metastases in patients with 
vulvar cancer and unilateral sentinel lymph node metastases. 
Acta Obstet Gynecol Scand. 2021;00:1–6. https://doi.
org/10.1111/aogs.14157
